ArticlePloS one2026
Enhanced fibrinolytic enzyme production by Oidiodendron maius through green bioprocessing of agro-industrial residue.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombosis denotes the formation of blood clots within arteries and veins, representing a primary etiological factor in cardiovascular diseases often culminating in fatal outcomes. Prompt resolution of thrombotic disorders is achieved through expedited fibrinolysis facilitated by the administration of fibrinolytic enzymes, which constitute the optimal therapeutic approach. This research aimed to enhance the production of fibrinolytic enzymes through the cultivation of indigenously isolated strains of Oidiodendron maius using physical and chemical mutagenesis techniques. Fibrinolytic enzyme activity from mutant strains was validated by enzyme assays followed by purification using ammonium sulfate precipitation, desalting, ion exchange chromatography, gel filtration chromatography, and SDS-PAGE. Various kinetic and thermodynamic parameters were systematically optimized to maximize enzyme activity. In O. maius, the ethidium bromide mutant strain showed better results as compared to the other mutants with specific activity of 1642.24 U/mg and 0.5 mg/mL protein content compared to the wild-type strain which 90.20 U/mg specific activity and 3.7 mg/mL protein content. The optimum temperature and pH were 35°C and 7.5, respectively. The findings indicated that treating O. maius with ethidium bromide resulted in the generation of better mutants with enhanced enzyme activities compared to wild-type and other mutant strains. With optimization of multiple parameters, these strains demonstrate significant potential for enhanced fibrinolytic enzyme production by the usage of wheat bran as substrate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.